AstraZeneca Pharma shares rose on receiving nod from the CDSCO, to import for sale and distribution of Benralizumab 30 mg/ml ...

Bangalore: AstraZeneca Pharma India Limited has received regulatory approval from the Central Drugs Standard Control ...

Through this approval, Benralizumab is indicated as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).

Discover a study that highlights a potentially critical role for the BDNF-NTRK2 pathway in EoE symptom development.

Investigating allergy prevention, this research highlights early intervention strategies and the promise of biologic ...

Allergen immunotherapy with omalizumab, mepolizumab, benralizumab, reslizumab, dupilumab, and tezepelumab has shown promising outcomes in preventing asthma exacerbations. Real-world studies ...

And in a separate development the Japanese regulator approved AZ’s new respiratory drug Fasenra (benralizumab), as an add-on treatment for bronchial asthma. An injected drug, Fasenra was ...

More than 50% of patients with severe asthma have high eosinophil levels, making them candidates for biologic therapies like Nucala and other drugs like AstraZeneca’s Fasenra (benralizumab ...

The Indian rupee closed nearly at at 85.5775 versus the U.S. dollar, capping a choppy trading session influenced by routine importer dollar bids and a mild rise in the dollar index. We maintain ...

Roshni Naik, MD, allergist at Mount Sinai Health System, discusses the history of present illness for a case of severe asthma with nasal polyps: "Patient is a 45 year-old male with a past medical ...